Ligand Pharmaceuticals
LGND
275 hedge funds and large institutions have $2.32B invested in Ligand Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 75 increasing their positions, 130 reducing their positions, and 50 closing their positions.
6.98% less ownership
Funds ownership: 203.87% → 196.89% (-7%)
10% less funds holding
Funds holding: 305 → 275 (-30)
18% less capital invested
Capital invested by funds: $2.85B → $2.32B (-$521M)
42% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 130
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 50
82% less call options, than puts
Call options by funds: $36.6M | Put options by funds: $200M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$44.2M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$16.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$14.9M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$13.6M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$33.9M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$21.1M |
| 3 |
Goldman Sachs
New York
|
-$20.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$18M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$17.4M |
LGND Hedge Fund Activity: Q3 2019 in Review
275 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2019, worth a combined $2.32B — down 18% from $2.85B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of LGND and 21 opened new positions — a net loss of 29 holders — while 130 trimmed existing stakes and 75 added.
The largest buyer was William Blair Investment Management, adding an estimated $44.2M. The largest seller was Invesco, cutting an estimated $33.9M.
- 275 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2019, down from 305 in Q2 2019.
- Funds reported $2.32B of Ligand Pharmaceuticals stock for Q3 2019, down 18% quarter-over-quarter.
- 21 funds opened new Ligand Pharmaceuticals positions in Q3 2019 and 50 closed out, a net change of -29 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2019 was William Blair Investment Management, an estimated $44.2M added.
- The largest Ligand Pharmaceuticals seller in Q3 2019 was Invesco, an estimated $33.9M sold.
Based on aggregated 13F filings for Q3 2019.